Eyepoint Pharmaceuticals (NASDAQ:EYPT) Upgraded at Wall Street Zen

Wall Street Zen upgraded shares of Eyepoint Pharmaceuticals (NASDAQ:EYPT) from a strong sell rating to a sell rating in a research note released on Saturday morning.

A number of other equities research analysts also recently issued reports on the stock. Guggenheim reissued a “buy” rating and set a $68.00 price objective on shares of Eyepoint Pharmaceuticals in a research report on Wednesday, June 24th. HC Wainwright reaffirmed a “neutral” rating on shares of Eyepoint Pharmaceuticals in a report on Tuesday, August 18th. JPMorgan Chase & Co. reiterated a “neutral” rating on shares of Eyepoint Pharmaceuticals in a research report on Monday, August 17th. Jefferies Financial Group cut their price target on Eyepoint Pharmaceuticals to $8.00 and set a “buy” rating for the company in a report on Monday, August 17th. Finally, Weiss Ratings cut Eyepoint Pharmaceuticals from a “sell (d-)” rating to a “sell (e+)” rating in a research report on Monday, August 17th. One analyst has rated the stock with a Strong Buy rating, four have given a Buy rating, five have issued a Hold rating and one has issued a Sell rating to the stock. According to MarketBeat.com, the stock currently has an average rating of “Hold” and an average price target of $28.11.

Eyepoint Pharmaceuticals Trading Down 8.5%

EYPT opened at $4.87 on Friday. The company has a market cap of $419.85 million, a price-to-earnings ratio of -1.30 and a beta of 1.76. The company’s 50 day moving average is $12.41 and its 200 day moving average is $13.32. Eyepoint Pharmaceuticals has a 12-month low of $3.95 and a 12-month high of $19.11.

Eyepoint Pharmaceuticals (NASDAQ:EYPT) last announced its earnings results on Wednesday, August 5th. The company reported ($1.09) earnings per share (EPS) for the quarter, missing the consensus estimate of ($1.01) by ($0.08). Eyepoint Pharmaceuticals had a negative net margin of 10,994.73% and a negative return on equity of 135.81%. The business had revenue of $0.51 million for the quarter, compared to the consensus estimate of $0.45 million. As a group, analysts predict that Eyepoint Pharmaceuticals will post -3.51 EPS for the current fiscal year.

Institutional Investors Weigh In On Eyepoint Pharmaceuticals

A number of institutional investors and hedge funds have recently bought and sold shares of the business. KBC Group NV bought a new position in shares of Eyepoint Pharmaceuticals in the first quarter worth about $29,000. Mirae Asset Global Investments Co. Ltd. raised its stake in Eyepoint Pharmaceuticals by 51.0% during the 4th quarter. Mirae Asset Global Investments Co. Ltd. now owns 4,023 shares of the company’s stock valued at $74,000 after purchasing an additional 1,358 shares during the period. Russell Investments Group Ltd. purchased a new position in Eyepoint Pharmaceuticals in the 3rd quarter worth approximately $76,000. Tower Research Capital LLC TRC lifted its holdings in Eyepoint Pharmaceuticals by 218.3% in the 2nd quarter. Tower Research Capital LLC TRC now owns 8,700 shares of the company’s stock worth $82,000 after purchasing an additional 5,967 shares in the last quarter. Finally, California State Teachers Retirement System boosted its stake in Eyepoint Pharmaceuticals by 20.6% in the 4th quarter. California State Teachers Retirement System now owns 4,654 shares of the company’s stock worth $85,000 after purchasing an additional 794 shares during the period. 99.41% of the stock is owned by institutional investors.

About Eyepoint Pharmaceuticals

Eyepoint Pharmaceuticals, Inc is a biopharmaceutical company focused on the development and commercialization of therapies for the treatment of ocular diseases. The company’s proprietary platform centers on sustained-release formulations designed to improve drug delivery to the posterior segment of the eye, addressing conditions that often require repeated intravitreal injections or intensive topical regimens. Eyepoint’s commercial strategy combines in-house sales and marketing capabilities with targeted partnerships to bring its therapies to ophthalmologists and retina specialists across the United States.

Eyepoint’s lead products include YUTIQ, a fluocinolone acetonide intravitreal implant indicated for the prevention of relapse in non-infectious uveitis affecting the posterior segment of the eye, and DEXYCU, a dexamethasone intraocular suspension approved for postoperative inflammation following ocular surgery.